{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:36Z","timestamp":1772119536950,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10147-023-02402-1","type":"journal-article","created":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T01:01:35Z","timestamp":1693098095000},"page":"1501-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer"],"prefix":"10.1007","volume":"28","clinical-trial-number":[{"clinical-trial-number":"umin000006105","registry":"10.18810\/umin-japan"},{"clinical-trial-number":"umin000006755","registry":"10.18810\/umin-japan"},{"clinical-trial-number":"umin000006045","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1213-2732","authenticated-orcid":false,"given":"Kazuhiro","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Fujitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiya","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tsuburaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for HERBIS-2, HERBIS-4A, XParTS I. I. study investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"2402_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"2402_CR2","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903\u20132909","journal-title":"J Clin Oncol"},{"key":"2402_CR3","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991\u20134997","journal-title":"J Clin Oncol"},{"key":"2402_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunnigham","year":"2008","unstructured":"Cunnigham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36\u201346","journal-title":"N Engl J Med"},{"key":"2402_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215\u2013221","journal-title":"Lancet Oncol"},{"key":"2402_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, Kang WK, Shin DB et al (2009) Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666\u2013673","journal-title":"Ann Oncol"},{"key":"2402_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"2402_CR8","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968\u20133976","journal-title":"J Clin Oncol"},{"key":"2402_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick F, Kang YK, Chung HC et al (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490\u2013499","journal-title":"Lancet Oncol"},{"issue":"24","key":"2402_CR10","first-page":"1","volume":"2021","author":"Japanese gastric cancer treatment guidelines","year":"2018","unstructured":"Japanese gastric cancer treatment guidelines (2018) 5th edition. Gastric Cancer 2021(24):1\u201321","journal-title":"Gastric Cancer"},{"key":"2402_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejca.2018.06.026","volume":"101","author":"K Nishikawa","year":"2018","unstructured":"Nishikawa K, Tsuburaya A, Yoshikawa T et al (2018) A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). Eur J Cancer 101:220\u2013228","journal-title":"Eur J Cancer"},{"key":"2402_CR12","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s10147-020-01711-z","volume":"25","author":"H Kawakami","year":"2020","unstructured":"Kawakami H, Fujitani K, Matsuyama J et al (2020) Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naive advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. Int J Clin Oncol 25:1635\u20131643","journal-title":"Int J Clin Oncol"},{"key":"2402_CR13","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1634\/theoncologist.2018-0175","volume":"23","author":"H Kawakami","year":"2018","unstructured":"Kawakami H, Takeno A, Endo S et al (2018) Randomized, open-label phase ii study comparing capecitabine-cisplatin every 3 weeks with S-1-cisplatin every 5 weeks in chemotherapy-naive patients with HER2-negative advanced gastric cancer: OGSG1105, HERBIS-4A trial. Oncologist 23:1411-e147","journal-title":"Oncologist"},{"key":"2402_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/sj.bjc.6604536","volume":"99","author":"JL Lee","year":"2008","unstructured":"Lee JL, Kang YK, Kang HJ et al (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 99:584\u201390","journal-title":"Br J Cancer"},{"key":"2402_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/FPC.0000000000000320","volume":"28","author":"MJ Kim","year":"2018","unstructured":"Kim MJ, Kong SY, Nam BH et al (2018) A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results. Pharmacogenet Genom 28:23\u201330","journal-title":"Pharmacogenet Genom"},{"key":"2402_CR16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","volume":"48","author":"GM Kim","year":"2012","unstructured":"Kim GM, Jeung HC, Rha SY et al (2012) A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 48:518\u2013526","journal-title":"Eur J Cancer"},{"key":"2402_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082798","volume":"8","author":"MM He","year":"2013","unstructured":"He MM, Wu WJ, Wang F et al (2013) S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis. PLoS ONE 8:e82798","journal-title":"PLoS ONE"},{"key":"2402_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10120-015-0587-8","volume":"19","author":"E Ter Veer","year":"2016","unstructured":"Ter Veer E, Mohammad NH, Lodder P et al (2016) The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. Gastric Cancer 19:696\u2013712","journal-title":"Gastric Cancer"},{"key":"2402_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.21037\/apm.2020.04.26","volume":"9","author":"Z Feng","year":"2020","unstructured":"Feng Z, Yan P, Hou X et al (2020) The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials. Ann Palliat Med 9:883\u2013894","journal-title":"Ann Palliat Med"},{"key":"2402_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M et al (2015) Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA 313:1657\u201365","journal-title":"JAMA"},{"key":"2402_CR21","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.3390\/cancers14225673","volume":"14","author":"H Kawakami","year":"2022","unstructured":"Kawakami H, Nishikawa K, Shimokawa T et al (2022) Histology classification highlights differences in efficacy of S-1 versus capecitabine, in combination with cisplatin, for her2-negative unresectable advanced or recurrent gastric cancer with measurable disease. Cancers 14:5673","journal-title":"Cancers"},{"key":"2402_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/annonc\/mdv316","volume":"26","author":"MH Ryu","year":"2015","unstructured":"Ryu MH, Baba E, Lee KH et al (2015) Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and\/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol 26:2097\u20132101","journal-title":"Ann Oncol"},{"key":"2402_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jjco\/hyx044","volume":"47","author":"A Takashima","year":"2017","unstructured":"Takashima A, Iizumi S, Boku N (2017) Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world. Jpn J Clin Oncol 47:583\u2013589","journal-title":"Jpn J Clin Oncol"},{"issue":"7517","key":"2402_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202\u2013209","journal-title":"Nature"},{"key":"2402_CR25","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547\u20131553","journal-title":"J Clin Oncol"},{"key":"2402_CR26","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1093\/annonc\/mdx275","volume":"28","author":"JA Ajani","year":"2017","unstructured":"Ajani JA, Abramov M, Bondarenko I et al (2017) A phase III trial comparing oral S-1\/cisplatin and intravenous 5-fluorouracil\/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol 28:2142\u20132148","journal-title":"Ann Oncol"},{"key":"2402_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548\u201357","journal-title":"Anticancer Drugs"},{"key":"2402_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 26:141\u2013148","journal-title":"Ann Oncol"},{"key":"2402_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet 398:27\u201340","journal-title":"The Lancet"},{"key":"2402_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234\u2013247","journal-title":"Lancet Oncol"},{"key":"2402_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku N, Ryu MH, Kato K et al (2019) Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 30:250\u201358","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02402-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T23:11:10Z","timestamp":1698707470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02402-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02402-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3109064\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazuhiro Nishikawa has received\u00a0honoraria for\u00a0lectures\u00a0from Bristol-Myers Squibb Co. Ltd.,\u00a0Daiichi-Sankyo Co. Ltd.,\u00a0EA Pharma Co. Ltd.,\u00a0Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd.,\u00a0Otsuka Pharmaceutical Co. Ltd.,\u00a0and Taiho Pharmaceutical Co. Ltd.\u00a0Hisato Kawakami has received consulting fees from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Daiichi-Sankyo Co. Ltd.; honoraria from Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. Yukinori Kurokawa has received honoraria and research funding from Taiho Pharmaceutical. Taroh Satoh has received departmental research grants from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Daiichi-Sankyo Co. Ltd.,\u00a0Hutchmed, Parexell, and BeiGene, and honoraria from Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., and Daiichi-Sankyo Co. Ltd. All remaining authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This\u00a0trial was conducted in compliance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of the Japanese Ministry of Health, Labour and Welfare. This trial was approved by the institutional review boards or ethics committees at all participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}